Breast Cancer International Research Group Ltd.

NEW YORK, June 15, 2022 /PRNewswire/ -- As per Zion Market Research study, The global tissue expander market delivered revenue growth of USD 661.6 million in 2021 and is projected to expand at a CAGR of nearly 7.45 percent to reach USD 1,236.78 million by 2028. The report covers key driving elements along with the challenges and & restraints and their impact on the overall market expansion. The report also explores significant opportunities that could boost the market growth during the forecast period Key Industry Insights & Finding of the Tissue Expander Market Reports: As per the analysis shared by our research analyst, the Tissue Expander Market is expected to grow annually at a CAGR of around 7.45 % (2022-2028). Through the primary research, it was established that the Tissue Expander Market was valued approximately USD 661.6 Million in 2021 and is projected to reach to roughly USD 1,236.78 Million by 2028. North America tissue expander market held the highest share, accounting for 35 percent of the entire market. The rapid expansion of this region is due to the high prevalence of breast cancer, which has increased the use of foreskin restoration and tissue expanders in the North America region. The expansion of the tissue expander market in the region is being fueled by favorable government initiatives and an increasing number of research collaborations. Zion Market Research published the latest report titled as 'Tissue Expander Market By Shape (Anatomical, Round, Rectangular, Crescent, Others), Application (Breast Reconstruction, Forehead Skin & Scalp Reconstruction, Face & Neck Reconstruction, Others), End-Users (Hospitals, Cosmetology Clinics, Ambulatory Surgical Centers, Others), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.' into their research database. Tissue Expander Market: Overview Tissue expanders are medical implants that are commonly utilized in cosmetic and trauma-related reconstructive operations. When these devices are implanted, they operate like a balloon that expands to stretch the tissue or skin covering the implant. Tissue expansion techniques including these implants are common in scalp reconstruction, breast reconstruction, and maxillofacial purposes. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 190 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Tissue Expander Market: Growth Drivers An upsurge in reconstruction surgeries across the world is expected to boost the market growth. One of the primary reasons driving the growth of the tissue expander market is the rise in the number of reconstructive procedures performed throughout the world. The rise in the prevalence of breast cancer, as well as the increased usage of tissue expanders in reconstruction operations such as scalp reduction surgery and reconstruction of the face, arms, neck, and legs, are driving market expansion. Further, the rise in the number of trauma incidents and serious car accidents, as well as the rising popularity of reconstructive surgeries like skin implants and skin grafting treatments, all have a positive impact on the market growth. In addition, the tissue expander industry benefits from lifestyle changes, increased healthcare spending, and increased public awareness of health issues. Tissue Expander Market: Restraints High costs allied with reconstruction surgeries may hamper the market growth. The high expenses linked with reconstruction procedures of breasts, face, and other body parts are among the major obstacles to the global tissue expander markets expansion. The high expense of breast reconstruction surgery in poor nations like South Africa is predicted to deter people from considering these procedures. The average breast reconstruction surgery costs between USD 3000 to USD 10,000. Furthermore, in developing countries, the average cost of a mastectomy is USD 4,500. Hormonal treatment, conventional chemotherapy, biological therapies, and radiation therapy are among the post-surgery procedures that cost between USD 5,500 to USD 30,000. Directly Purchase a Copy of the Report at Global Tissue Expander Market: Opportunities An increase in medical tourism is expected to support the market growth. In Asia Pacific and Latin American nations such as China, India, Japan, Brazil, Columbia, Costa Rica, and others, health or medical tourism is the current trend. Breast reconstruction is one of the most common operations performed in plastic surgery in these nations. The demand for plastic surgery is predicted to increase in these regions as a result of reduced treatment costs and an increase in the number of procedures done. In the following projected years, this is expected to support demand for tissue expanders by 25 percent of present levels. Global Tissue Expander Market: Challenges Prolonged tissue expander techniques and inadequate tissue expander supplies in underdeveloped economies pose a major challenge to market growth. The use of a tissue expander necessitates a more involved procedure. To be effective, the method necessitates a careful selection of the patient, meticulous preparation, and faultless execution. The operation typically lasts 8 to 12 weeks and requires two surgical sittings. Any compromise in this technique can lead to negative results and complexity, some of which are slight and allow the operation to continue in order to achieve the anticipated aim, while others are severe and result in the procedure being abandoned without achieving the intended goal. Furthermore, tissue expanders are in short supply in poor countries. Due to all such factors, the global tissue expander market expansion is being hampered. Global Tissue Expander Market: Segmentation The global tissue expander market is categorized based on shape, application, end-users, and region. Based on the shape, the market is bifurcated into round, anatomical, crescent, rectangular, and others. The applications of the market are segregated as face & neck reconstruction, breast reconstruction, forehead skin & scalp reconstruction, and others. By end-users, the market is bifurcated into hospitals, ambulatory surgical centers, cosmetology clinics, and others. Get More Insight before Buying at : List of Key Players of Tissue Expander Market: PMT Corporation ALLERGAN Mentor Worldwide LLC GC Aesthetics Sientra Inc. GROUPE SEBBIN SAS KOKEN CO.LTD. LABORATOIRES ARION POLYTECH Health & Aesthetics GmbH Wanhe Oxtex Ltd. Eurosurgical Ltd. Key questions answered in this report: What are the growth rate forecast and market size for Tissue Expander Market? What are the key driving factors propelling the Tissue Expander Market forward? What are the most important companies in the Tissue Expander Market Industry? What segments does the Tissue Expander Market cover? How can I receive a free copy of the Tissue Expander Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments: In Sept 2021, JOYTM, a revolutionary patient-centric breast aesthetics approach, has been announced by Establishment Labs Holdings Inc. Women who select JOY will get Establishment Labs' latest new-gen Motiva Ergonomix2® implants through a network of highly trained plastic surgeons and the sector's most comprehensive patient support program. JOY is being revealed at the 6th World Symposium on Ergonomic Implants, which is being held this week in Gardone Riviera, Italy, and is being addressed by over 200 plastic surgeons. In May 2021, Vizient, Inc. has awarded Sientra, Inc. with an Innovative Technology contract for their AlloX2 tissue expander. The contract went into force on May 1st, and it informs Vizient members about AlloX2's unique traits that might benefit the healthcare business. Vizient's Innovative Technology Program awards contracts based on the recommendations of healthcare specialists who serve on a Vizient member-led council that evaluates product applications. Regional Dominance: North America to dominate the global market during the forecast period. In 2021, North America tissue expander market held the highest share, accounting for 35 percent of the entire market. The rapid expansion of this region is due to the high prevalence of breast cancer, which has increased the use of foreskin restoration and tissue expanders in the region. Moreover, the expansion of the tissue expander market in the region is being fueled by favorable government initiatives and an increasing number of research collaborations. Furthermore, Asia Pacific region is expected to grow at the highest CAGR rate. This rapid increase in the market growth is due to variables such as an increase in the number of cases of trauma and catastrophic traffic accidents in nations such as India. Also, the increase in tissue inflammation is assumed to be the case in the nation. Moreover, the increasing cosmetics sector in emerging is fueling the tissue expander market's growth in Asia Pacific region. Global Tissue Expander Market is segmented as follows: Tissue Expander Market: By Shape Outlook (2022-2028) Anatomical Round Rectangular Crescent Others Tissue Expander Market: By Application Outlook (2022-2028) Breast Reconstruction Forehead Skin and Scalp Reconstruction Face and Neck Reconstruction Others Tissue Expander Market: By End Users Outlook (2022-2028) Hospitals Cosmetology Clinics Ambulatory Surgical Centers Others Tissue Expander Market: By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Press Release For Tissue Expander Market: Browse Other Related Research Reports from Zion Market Research Digital Patient Monitoring Devices Market - Global Industry Analysis : The global Digital Patient Monitoring Devices Market accrued earnings worth approximately 63.1 (USD Billion) in 2020 and is predicted to gain revenue of about 447.3(USD Billion) by 2028, is set to record a CAGR of nearly 24.1% over the period from 2021 to 2028. Viscosity Reducing Agents Market - Global Industry Analysis : The global Viscosity Reducing Agents Market accrued earnings worth approximately 10.1 (USD Billion) in 2020 and is predicted to gain revenue of about 19.2 (USD Billion) by 2028, is set to record a CAGR of nearly 5.1% over the period from 2021 to 2028. Leadless Pacemaker Systems Market - Global Industry Analysis : The global Leadless Pacemaker Systems Market accrued earnings worth approximately 55 (USD Million) in 2021 and is predicted to gain revenue of about 98 (USD Million) by 2028, is set to record a CAGR of nearly 10.1% over the period from 2022 to 2028. Browse through Zion Market Research's coverage of the Global Medical Device Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - Logo: SOURCE Zion Market Research

NEW YORK, June 9, 2022 /PRNewswire/ -- The Global Breast Imaging Market is expected to clock US$ ~ 8.46 billion by 2031 owing to the rising prevalence of breast cancer, growing awareness of early diagnosis, and the rising new product launches by players in the market. According to the latest report published by Growth Plus Reports, titled "Breast Imaging Market by Technology (Ionizing Technology and Non-Ionizing Technology), Materials (Hospitals & Clinics and Diagnostics Center)–Global Outlook & Forecast 2021-2031 "The Breast Imaging market was worth ~US$ 2.76 billion in 2020 and is expected to grow at a CAGR of 10.7% during the forecast period, 2021-2031 Get a sample PDF of this research report: Growth Engines Breast cancer is the second leading cause of death in women globally. The rising incidence of breast cancer, the rising awareness of early detection of breast cancer, and rising investments in the development of new imaging systems are some of the factors propelling the market growth. Companies in the market are focused on adopting various organic as well as inorganic strategies. For instance, in February 2021, SmartBreast Corporation formed a partnership with FoxSemicon Integrated Technologies, Inc. to manufacture molecular breast imaging (MBI) systems. FoxSemicon has invested in SmartBreast Corporation and will contract manufacturer two MBI systems acquired by SmartBreast i.e. the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. Such strategic partnerships or collaborations help the company to strengthen their foothold in the market. The global breast imaging market has been analyzed from three perspectives: Technology, End User, and Region. Restraints However, complications related to breast implants are expected to restrain the market growth to a certain extent. Common complications associated with breast implants include infection, chronic breast pain, rupturing or leaking of the implant, necrosis, and breast or nipple numbness. Furthermore, among the patients who had undergone reconstruction surgery, around 45% of patients with silicone gel implants and around 20% with saline implants underwent at least one additional operation within 3 years. Whereas, around 25% of patients with silicone implants and 8% of patients with saline implants removed their implants. Therefore, complications associated with implants and an increase in the overall cost due to these complications are expected to limit the growth of the market. Excerpts from 'By Technology Segmentation' Based on technology, the breast imaging market has been segmented into :- Ionizing Technology Non-Ionizing Technology The Ionizing technology segment is further bifurcated into mammography, molecular breast imaging (MBI), positron emission tomography-computed tomography (PET-CT), positron emission mammography (PEM), and cone-beam computed tomography (CBCT). The mammography segment is further sub-segmented into 3D breast tomosynthesis, analog mammography, and full-field digital mammography (FFDM). The non-ionizing technology segment is further categorized as breast MRI, breast ultrasound, automated whole-breast ultrasound (AWBU), breast thermography, optical imaging, and electric impedance tomography. The non-ionizing breast imaging segment is anticipated to grow at the highest CAGR during the projected period. The advantages offered by these imaging technologies compared to ionizing breast imaging systems such as higher sensitivity, relatively low cost, and easy accessibility are some of the factors that are expected to increase the adoption of these systems in the coming years. Moreover, technological advancements and new product launches are fueling the growth of this segment. Ask here for more customization [email protected] Excerpts from 'By Region Segmentation' Regionally, the global breast imaging market has been segmented into North America Europe Asia Pacific The Rest of the World (RoW). North America held the largest share of the global breast imaging market in 2020. The growing old age population, the rising incidence of breast cancer, and higher awareness among the population regarding early diagnosis of breast cancer are some of the factors driving the market growth in this region. Moreover, a favorable reimbursement scenario for breast imaging is further boosting the breast imaging market growth in this region. Excerpts from 'Competitive Landscape' Some of the prominent players operating in the global breast imaging market include: - General Electric Company Hologic, Inc Siemens Healthcare Koninklijke Philips N.V Fujifilm Corporation Planmed OY Canon Medical Systems Dilon Medical Technologies, Inc Aurora Healthcare US Corp Delphinus Medical Technologies, Inc Among others Table Of Contents 1 INTRODUCTION 1.1 Market Ecosystem 1.2 Geographic Scope 1.3 Timeline Under Consideration • Historical Years – 2018 & 2019 • Base Year – 2020 • Forecasted Years – 2021 to 2031 1.4 Currency Used in the Report 2 RESEARCH METHODOLOGY 2.1 Research Approach 2.2 Data Collection Methodology 2.3 Data Sources 2.3.1 Secondary Sources 2.3.2 Primary Sources 2.4 Market Estimation Approach 2.4.1 Bottom Up 2.4.2 Top Down 2.5 Market Forecasting Model 2.6 Limitations and Assumptions 3 PREMIUM INSIGHTS 3.1 Current Market Trend (COVID-19 Perspective) 3.2 Key Players & Their Competitive Positioning (2020) 4 MARKET DYNAMICS 4.1 Drivers 4.2 Restraints/Challenges 4.3 Opportunities 5 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY IMPLANT TYPE 5.1 Silicone Implant 5.2 Saline Implant 6 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY APPLICATION 6.1 Breast Reconstruction 6.2 Breast Augmentation 7 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY END USER 7.1 Hospitals 7.2 Cosmetology Clinics 7.3 Others (Ambulatory Care Center, Etc.) TOC Continued… VALUE PROPOSITIONS RELATED TO THE REPORT: Powered with Complimentary Analyst Hours and Expert Interviews with Each Report Comprehensive quantitative and qualitative insights at segment and sub-segment level Covid 19 impact trends and perspective Granular insights at global/regional/country level Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment Blanket coverage on competitive landscape Winning imperatives Exhaustive coverage on 'Strategic Developments' registered by leading players of the market CUSTOMIZATION OPTIONS: Distributor Landscape Assessment Pricing Intelligence Customer Base Assessment Investment & Initiatives Analysis 'Business Profile' of Key Players Buy this Premium Research Report at About Us: Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020. Contact: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +91 96545 76783 Web: Follow Us: LinkedIn | Twitter SOURCE Growth Plus Reports

SAN ANTONIO, Dec. 5 /PRNewswire/ -- A Docetaxel (Taxotere(R))-based regimen reduced the relative risk of death in women with early stage breast cancer by 30 percent and lowered the relative risk of the cancer returning by 28 percent when compared to a standard adjuvant (post-surgery) regimen after 55-month follow-up. The results of BCIRG 001, the first phase III study evaluating Taxotere after breast surgery, were presented at the San Antonio Breast Cancer Symposium (SABCS) by the Breast Cancer International Research Group (BCIRG) today. "Taxotere continues to demonstrate its effectiveness across various stages of breast cancer, and this study indicates that women with early stage breast cancer and their physicians should seriously consider a Taxotere-based treatment, like the TAC regimen tested in the BCIRG 001 trial, to significantly prolong disease-free survival and survival," said Miguel Martin M.D. from the Medical Oncology Department, Hospital Universitario San Carlos, Madrid, Spain, chairman of GEICAM. Study Design The BCIRG 001 study was designed to determine if Taxotere, one of the most active agents in advanced breast cancer, would also have benefits for women with early stage disease. Study participants received either a post-surgery regimen of Taxotere, doxorubicin (Adriamycin), and cyclophosphamide (Cytoxan), known as TAC, or the widely used standard regimen of 5-fluorouracil, doxorubicin and cyclophosphamide, known as FAC. BCIRG 001 enrolled 1,491 pre- and post-menopausal women with early breast cancer at 111 sites in 20 countries; 745 patients were randomized to receive TAC and 746 to receive FAC. The study was designed to perform analyses on subgroups of women based on hormonal receptor status (hormone-receptor-positive or hormone-receptor-negative tumors) and nodal involvement (one-to-three or four-plus axillary lymph nodes). Tumor samples were prospectively collected for 95 percent of the patients. Hormonal receptor status, Her2neu amplification (FISH) as well as other tumor characteristics were centrally reviewed by an independent pathologist. Study Results At five years follow-up, 75 percent of patients on TAC and 68 percent of patients on FAC were disease-free. This corresponds to a 28 percent reduction in the relative risk of recurrence (p=0.0010). This also resulted in a survival advantage for patients treated with TAC. Eighty-seven percent of patients on TAC and 81 percent of patients on FAC were alive, which represents a 30 percent reduction in relative risk of mortality (p=0.0080) in favor of TAC patients. The significant benefits in favor of the Taxotere arm were observed in both hormone-receptor-positive (HR+) and hormone-receptor-negative (HR-) patients, with a reduction in the recurrence of disease of 27 percent and 34 percent respectively. A significant disease-free survival benefit was also observed independent of Her2neu expression. "These robust and mature results indicate that Taxotere in combination with doxorubicin and cyclophosphamide help women live longer and reduce the risk of cancer relapse," said John R. Mackey, M.D., FRCP(C), Department of Oncology, University of Alberta, and Cross Cancer Institute, Edmonton, Canada. "After almost five years of follow-up, we are confident that this Taxotere-based treatment can cure more women than one of the standard chemotherapy regimens we currently use." "This study confirms that Taxotere is a very compelling component of future combinations being developed for the treatment of early stage breast cancer with new therapies coming from biological research," stated Dennis J. Slamon, M.D., Ph.D. Chief, Division of Hematology-Oncology; UCLA School of Medicine, Los Angeles. Both regimens were administered with high compliance, as 97 percent patients on FAC and 91 percent patients on TAC received the planned six cycles of chemotherapy. The TAC regimen was associated with a higher incidence of febrile neutropenia (a fever that occurs at the time when white blood cells are decreased) compared with patients receiving FAC, but this did not result in significantly different or elevated rates of moderate to severe infections in patients who received TAC compared with FAC. There were no toxic deaths and no long-lasting toxicities with either treatment arm. "These results offer a promising new treatment option for reducing the risk of recurrence and mortality of early breast cancer patients," said Susan Braun, president and chief executive officer of the Susan G. Komen Breast Cancer Foundation. "The Komen Foundation strongly supports educating patients and physicians about the scientific benefits, as well as the high quality of patient care, associated with well-designed clinical trials." "BCIRG 001 is the first large adjuvant trial conducted by the Breast Cancer International Research Group. The TAC regimen constitutes the standard regimen for other trials with taxanes carried out by national and international cooperative groups," stated Charles Vogel, M.D., from the Cancer Research Network in Plantation, Florida. About Breast Cancer Breast cancer is an abnormal cell growth originating in breast tissue. If not diagnosed and treated early, these cells can invade surrounding tissue and spread through the blood and lymph node system. An estimated 211,300 women in the U.S. will be diagnosed with breast cancer this year, and an estimated 40,000 women will die from the disease. Worldwide, almost 1 million women are diagnosed with this disease each year. In the United States and Europe, it is the most common cancer among women, excluding skin cancer, and the second leading cause of cancer death among women. About BCIRG BCIRG is an academic global cooperative intergroup of oncology researchers dedicated to the global strategic development of promising new therapies for women with breast cancer. The goal of BCIRG is to identify and select the best compounds in their class (chemotherapy, hormone therapy, biologic modifiers and gene therapy) and to create global pivotal strategies of development in order to test these new treatments and bring them to patients in a timely manner. Academic rigor, speed, quality of processes and worldwide patient access are achieved through the interaction of the most advanced academic institutions in the world and a large global network of clinical investigators. BCIRG is a division of Cancer International Research Group, a not-for-profit organization. The study was sponsored by Aventis. Aventis manufactures docetaxel under the trade name Taxotere(R). BCIRG CONTACT: Emmanuelle Mekercke, Communication Manager of BCIRG,+331-58-10-08-97, Emmanuelle.Mekercke@cirg.org; International - AlexandraBenarous of GCI, +1-212-537-8297, onsite - +1-646-298-0363; or U.S. - JoMoseley of Cohn & Wolfe, +1-212-798-9736, onsite - +1-347-645-4793, both forBCIRG